May 18 Quick Takes: Temasek backs Wilson, Yamada to form G2 Bio; plus PathAI, Interius, Vedere II and more
Singapore-based Temasek will supply $200 million to G2 Management Co. Inc. to foster the development of therapies from the University of Pennsylvania's Gene Therapy Program, led by James Wilson. Serial entrepreneur and former Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) executive Tachi Yamada is a co-founder, as is Wilson. G2 said it will fund companies that develop next-generation gene therapies, including those for non-monogenic diseases.
Pathology research tools and services company PathAI Inc. raised $165 million in series C funding from a syndicate led by D1 Capital Partners and Kaiser Permanente. The company's partners use its AI-powered tools to improve diagnoses and treatments. Also participating were General Atlantic, Tiger Global Management, 8VC, Adage Capital Management, Biospring Partners, General Catalyst, KdT Ventures, Polaris Partners, Refactor Capital, Bristol Myers Squibb Co. (NYSE:BMY), Laboratory Corp. of America Holdings (NYSE:LH) and Merck Global Health Innovation Fund...